Friday, June 26, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 845 of 1,261

  1. US 8575196

    Oligomer-opioid agonist conjugates

    Nektar Therapeutics · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted

  2. US 8575170

    Flurbiprofen analogs and methods of use in treating cancer

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted

  3. US 2013289070

    Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines

    BAUSCH & LOMB [US] · Granted Oct 31, 2013 · Expires Oct 26, 2033

    granted

  4. EP 2656851

    Semuloparin zur Verbesserung der Überlebenschance von Krebspatienten

    AVENTIS PHARMA SA [FR] · Granted Oct 30, 2013 · Expires Oct 25, 2033

    granted

  5. US 8569242

    Method of treating degenerative disorders of the nervous system

    The Regents of the University of California · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  6. US 8569380

    Oligomer-tricyclic conjugates

    Nektar Therapeutics · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  7. US 8569379

    Use of rasagiline for the treatment of olfactory dysfunction

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  8. US 8569377

    Methods for treating spinal cord injury with a compound that inhibits a NCCA-ATP channel

    The United States of America as represented by the Department of Veteran Affairs · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  9. US 8569340

    AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  10. US 8569320

    Topical composition for the treatment of actinic keratosis

    Almirall Hermal GmbH · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  11. US 8569253

    Methods and compositions for gene inactivation

    Sangamo Biosciences, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  12. US 8569249

    Method for inhibiting activation of macrophages

    China Medical University · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  13. US 8568977

    Compositions and methods for diagnosis and treatment of tumors

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  14. US 8569028

    Method for encapsulation of microparticles

    The United States of America, as represented by the Secretary of the Agriculture · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  15. US 8568756

    Inhibition of quorum sensing-mediated processes in bacteria

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  16. US 8569343

    Oligomer-opioid agonist conjugates

    Nektar Therapeutics · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  17. US 8568769

    Particle-containing complex porous materials

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  18. US 8569448

    NMDAR biomarkers for diagnosis and treatment of traumatic brain injury and other disorders

    GRACE LABORATORIES, LLC · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  19. US 8569337

    Tri-cyclic pyrazolopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  20. US 8569225

    Targeting complement factor H for treatment of diseases

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  21. US 8569351

    Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

    Theravance, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  22. US 8568739

    Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  23. US 8568714

    Lys K endolysin is synergistic with lysostaphin against MRSA

    The United States of America, as represented by the Secretary of Agriculture · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  24. US 8568713

    Super fast-acting insulin compositions

    HALOZYME, INC. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.